Biotech news for Tuesday, June 2, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Vladimir Zakharov A screen of U.S. stocks with market capitalizations between $2B and $10B highlights Acadia Healthcare Company ( ACHC ), Waystar Holding ( WAY ), and BioCryst Pharmaceuticals ( BCRX ) among the market's most attractively valued companies relat…
Vladimir Zakharov A screen of U.S. stocks with market capitalizations above $10 billion highlights Centene Corporation ( CNC ), Pfizer ( PFE ), BioMarin Pharmaceutical ( BMRN ), and Bristol-Myers Squibb ( BMY ) among the market's most attractively valued compa…
Aditxt ( ADTX ) announced on Monday the appointment of Jeffrey M. Busch as interim chief executive officer of Aditxt, effective May 31, 2026. Busch , who has served as chief executive officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary…
Jonathan Kitchen Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny and micro-cap stocks often struggle to meet the profitability, growth,…
UCB and Biogen ( BIIB ) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.…
da-kuk/E+ via Getty Images Akeso ( AKESF ) said its experimental lung cancer treatment ivonescimab improved overall survival compared with a widely used immunotherapy-based regimen in a Phase 3 study of patients with advanced squamous non-small cell lung cance…
Morsa Images/DigitalVision via Getty Images Revolution Medicines ( RVMD ) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cance…
JHVEPhoto/iStock Editorial via Getty Images Incyte’s ( INCY ) immunotherapy Monjuvi, developed with Xencor ( XNCR ), will soon become a first-line option for a common type of lymphoma after late-stage trial data indicated on Saturday that the CD19-targeting mo…
Replimune ( REPL ) won over the FDA to submit a marketing application for its lead asset RP1 for the third time despite previous rejections, thanks to the intervention of White House officials, The Wall Street Journal reported, citing people familiar with the…
Celularity ( CELU ) announced on Friday that it received a Nasdaq notice for not filing its Q1 2026 Form 10-Q on time, leading to non-compliance with listing rules. However, there is no immediate impact on its stock, as it will continue to trade on the
C4 Therapeutics ( CCCC ) reached a 52-week high on Friday after a treatment developed by Bristol-Myers Squibb ( BMY ), similar to the company’s lead candidate, generated impressive survival data in a late-stage trial for multiple myeloma, a blood cancer. The u…
JHVEPhoto Shares of MannKind Corporation ( MNKD ) spiked on Friday after the U.S. Food and Drug Administration approved the company’s request to expand its inhaled insulin therapy, Afrezza, for children with diabetes. The inhalation powder developed using Mann…
The European Medicines Agency, the EU drug regulator, recommended that vaccine makers target the SARS-CoV-2 variant XFG when developing COVID-19 vaccines for the 2026/2027 immunization campaign. The EMA’s Emergency Task Force decided on the variant after revie…